Molecular Profile of CD34+ Stem/progenitor Cells According to JAK2V617F Mutation Status in Essential Thrombocythemia
Overview
Authors
Affiliations
Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.
Giai V, Secreto C, Freilone R, Pregno P Medicina (Kaunas). 2021; 57(10).
PMID: 34684081 PMC: 8537741. DOI: 10.3390/medicina57101043.
Early and late stage MPN patients show distinct gene expression profiles in CD34 cells.
Baumeister J, Maie T, Chatain N, Gan L, Weinbergerova B, de Toledo M Ann Hematol. 2021; 100(12):2943-2956.
PMID: 34390367 PMC: 8592960. DOI: 10.1007/s00277-021-04615-8.
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak J, Moliterno A Front Oncol. 2021; 11:641613.
PMID: 33777803 PMC: 7987816. DOI: 10.3389/fonc.2021.641613.
Spivak J Curr Treat Options Oncol. 2018; 19(2):12.
PMID: 29516275 DOI: 10.1007/s11864-018-0529-x.
Genomic landscape of megakaryopoiesis and platelet function defects.
Bianchi E, Norfo R, Pennucci V, Zini R, Manfredini R Blood. 2016; 127(10):1249-59.
PMID: 26787733 PMC: 4841296. DOI: 10.1182/blood-2015-07-607952.